We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Current development of chimeric antigen receptor T‐cell therapy for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma.
- Authors
Yamauchi, Nobuhiko; Maruyama, Dai
- Abstract
Chimeric antigen receptor (CAR) T‐cell therapy has become a commercially available treatment option for relapsed or refractory (r/r) diffuse large B‐cell lymphoma (DLBCL) with two or more lines of prior therapies, and recently for high‐risk r/r DLBCL with one prior line of therapy. The successful development of CAR T‐cell therapy for multiple relapsed DLBCL has led to a boom in subsequent trials that investigated its utility in patients with other r/r B‐cell lymphoma subtypes. However, CAR T‐cell therapy is a multistep process that includes leukapheresis and manipulation which take several weeks. Therefore, patients with rapidly progressing or bulky disease may not be able to complete the therapeutic regimen involving CAR T‐cell products. This raises the question of the generalizability of the results of pivotal studies to the entire population. In this review, we summarize the development of CAR‐T cell therapy for B‐cell lymphoma and discuss strategies to further improve the clinical outcomes of this treatment.
- Subjects
DIFFUSE large B-cell lymphomas; CHIMERIC antigen receptors; T cells; LYMPHOMAS
- Publication
European Journal of Haematology, 2024, Vol 112, Issue 5, p662
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.14166